A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis

被引：5

作者：

Uttervall, Katarina ^{[1
,2
]}

Admasie, Johannes ^{[1
,2
]}

Alici, Evren ^{[1
,2
]}

Lund, Johan ^{[1
,2
]}

Liwing, Johan ^{[1
]}

Aschan, Johan ^{[3
]}

Barendse, Mirjam ^{[3
]}

Deneberg, Stefan ^{[1
,2
]}

Mellqvist, Ulf-Henrik ^{[4
]}

Carlson, Kristina ^{[5
]}

Nahi, Hareth ^{[1
,2
]}

机构：

[1] Karolinska Inst Huddinge, Dept Med, Div Haematol, Stockholm, Sweden

[2] Karolinska Univ Hosp Huddinge, Haematol Ctr Karolinska, SE-14186 Stockholm, Sweden

[3] Janssen Cilag AB, Sollentuna, Sweden

[4] Boras Hosp, Dept Haematol, Boras, Sweden

[5] Univ Uppsala Hosp, Dept Haematol, Uppsala, Sweden

来源：

ACTA HAEMATOLOGICA | 2013年 / 130卷 / 01期

关键词：

High-dose therapy; Multiple myeloma; Vincristine; doxorubicin and dexamethasone regimen; DIAGNOSED MULTIPLE-MYELOMA; STEM-CELL TRANSPLANTATION; THALIDOMIDE PLUS DEXAMETHASONE; HIGH-DOSE MELPHALAN; INDUCTION THERAPY; POOR-PROGNOSIS; DELETION; CHEMOTHERAPY; VINCRISTINE; DOXORUBICIN;

D O I：

10.1159/000345422

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Induction therapy for multiple myeloma (MM) and remission status before high-dose treatment (HDT) have been shown to be prognostic factors for survival outcome, although the optimal induction therapy is yet to be defined. Methods: We conducted a retrospective analysis of the impact of induction therapy on survival outcome before and after HDT in MM patients. The study included 236 consecutive patients who underwent HDT. Results: One hundred and forty-two patients (62%) were treated with vincristine, doxorubicin and dexamethasone (VAD) or cyclophosphamide and betamethasone (CyBet) and 94 (38%) were treated with bortezomib, cyclophosphamide and betamethasone (VCB) as induction. Time to first and time to best response was faster in the VCB group than in the VAD/CyBet group, with 42 versus 75 (p < 0.001) and 54 versus 88 days (p < 0.001), respectively. After induction therapy, 49% of the patients in the VCB group and 38% in the VAD/CyBet group achieved a very good partial response or better. Multivariate analysis revealed younger age, lower International Staging System stage and induction treatment with VCB as variables associated with favourable time to progression. Conclusions:Outcome measured as response and time to progression before and after HDT in MM differs depending on type of induction treatment and suggests that VCB is a highly effective induction regimen that confers a post-HDT advantage. Copyright (C) 2013 S. Karger AG, Basel

引用

页码：7 / 15

页数：9